The use of the active botanical component of this medicine, Lespedeza, has traditionally been utilized to support the body’s excretory function. The genus is associated with diuretic effects, assisting in renal function, and assisting with water retention. Леспефлан is specifically utilized in the field of Nephrology as additional symptomatic support for managing the metabolic consequences of chronic renal insufficiency.

Management of Azotemia and Uremic Symptoms

This domain is commonly used to address azotemia, a systemic condition characterized by the pathological buildup of nitrogenous metabolites like urea and creatinine. It is applied across chronic kidney conditions to provide the therapeutic benefit of managing these high toxin levels, which helps patients cope more steadily with the difficult symptoms related to systemic imbalance associated with the metabolic burden of chronic renal insufficiency.

Supportive Management for Fluid Retention and Impaired Diuresis

The medicine is considered relevant in clinical contexts where additional support is needed for fluid balance management due to impaired kidney function. It may assist with addressing symptom clusters involving edema (fluid retention) and signs of impaired diuresis. Through fluid support, it provides supportive relief that may assist with easing the overall symptom load and supports general well-being during persistent phases of moderate renal impairment.

---

Quick Fact: Symptomatic Support for Chronic Renal Issues
Primary Therapeutic Goal	Supports the management of chronic renal insufficiency.
Targeted Symptoms	Symptoms linked to high urea and creatinine (azotemia) levels.
Complementary Benefit	Assists with fluid retention and impaired diuresis.
Clinical Context	Applied in contexts needing additional symptomatic support for systemic burden.

Eligibility Map: Who can and cannot use Леспефлан — Official Regulatory Information

The eligibility profile for Леспефлан is defined by official regulatory documents that specify which populations are approved for use and which are strictly excluded.

Eligibility Status

Category	Regulatory Status
Approved Population	Adults (18 years and older).
Contraindicated Populations	Children and adolescents (under 18 years), pregnant women, breastfeeding women, individuals with diagnosed alcoholism.
Contraindicated Conditions	Severe renal insufficiency, liver diseases, epilepsy, cerebral diseases, or a history of craniocerebral trauma.

---

Eligibility-Related Restrictions

Age Restriction

The medicine is strictly contraindicated in individuals under 18 years of age; use is established only for the adult population.

Physiological and Condition-Based Restrictions

Pregnancy and lactation are formal, absolute contraindications.

Due to the formulation's ethanol content, use is contraindicated in patients with alcoholism, pre-existing liver diseases, and specific neurological conditions. Furthermore, the drug is contraindicated in cases of severe renal insufficiency.

The official regulatory information for Леспефлан has been reviewed across major government regulatory sources, including those from the European Medicines Agency and the U.S. Food and Drug Administration. The official prescribing information does not contain explicit, mandatory warnings regarding interactions with other medicinal products, foods, or supplements. The regulatory profile is defined by the absence of formal restrictions across key interaction domains:

Interaction Domain	Regulatory Status
Contraindicated Combinations	None explicitly specified
Pharmacokinetic/Metabolic Interactions	None officially documented
Timing or Separation Rules	None explicitly required

The official regulatory profile for this product is characterized by the lack of explicit warnings across all standardized interaction categories. This means the government-approved documentation does not contain formal statements regarding contraindicated combinations or required dose-timing separations with other medicinal products. The profile effectively communicates that no specific, mandatory interaction restrictions are officially stated in the product's verifiable regulatory labeling. Consequently, the interaction classification lacks the formal severity ratings and explicit mechanistic details (such as CYP enzyme or transporter effects) typically defined for products with documented, clinically significant interactions. This structure reflects that specific, restrictive warnings have not been mandated by regulatory authorities.

How Леспефлан Works

Леспефлан functions by modulating renal solute transport and fluid dynamics, primarily targeting the nephron tubules. The active constituents, a complex mixture of flavonoids and polyphenols derived from Lespedeza capitata, exert their effect locally within the kidney parenchyma.

This mechanism involves the subtle influence of these compounds on ion transport mechanisms, including the Na^+/ K^+-ATPase pump and specific aquaporin channels, which are critical for water and solute reabsorption in the renal medulla and cortex. The resultant pathway modulation leads to altered osmotic gradients, promoting an increase in fluid filtration and the fractional excretion rate of solutes.

This downstream mechanistic cascade specifically enhances the renal clearance of nitrogenous waste products, such as urea and creatinine, which constitute non-protein nitrogen. The system-level physiological consequence is the net reduction in the circulating concentration of these uremic toxins and the maintenance of systemic volume homeostasis through regulated diuresis, without provoking significant disturbances in major electrolyte balance.

The administration of Леспефлан is governed by explicit instructions, which define the product's administration route, dose schedule, and course duration for adult use. The medicine is supplied as an Oral Solution intended for internal consumption.

Usage Parameter	Official Instruction
Route of Administration	Oral (Внутрь)
Standard Dosing	5 mL to 15 mL per dose
Frequency Pattern	3 to 4 times per day
Age-Group Rule	Restricted to the adult population (18 years and older)
Preparation Rule	The bottle must be shaken before measuring the dose.

The standardized dosing regimen requires a measure of 5 mL to 15 mL to be administered 3 to 4 times throughout the day, ensuring the active components are taken on a consistent daily schedule. This liquid form permits dilution with water prior to consumption, a key preparation step.

The protocol mandates a defined treatment course, with a typical duration ranging from 3 to 4 weeks. For extended administration, the course may be prolonged up to six weeks, based on professional guidance. Importantly, any subsequent course of treatment requires a mandatory 2 to 3 week break period to complete the prescribed cycle of use. Use outside of the adult population is prohibited.

Research evidence / Overview of studies for Леспефлан

---

Evidence for Symptomatic Management of Azotemia

This section will summarize the type of research available, including pre-clinical and comparative animal studies, that has explored the research related to the body's processes for eliminating high levels of nitrogenous waste, such as urea and creatinine.

Research has primarily evaluated the effects of Леспефлан or its active extract in pre-clinical comparative studies using animal models. The research describes measurements related to systemic or functional imbalance, particularly looking at levels of urea and creatinine in the blood. The findings describe patterns observed in the studies where the administration of the extract was associated with changes in these nitrogenous waste biomarkers in the observed animal populations. These research scenarios provide insight into short-term changes in specific measured parameters.

Research on Supportive Management for Fluid Retention

This block will describe the studies and scientific literature reviews that have explored the product's associated diuretic action, focusing on how researchers measured fluid balance, diuresis, and the plant extract's traditional uses for water retention.

Research describes measurements related to physiological strain or stress, specifically looking at measurements of diuresis (urine output) and the excretion of electrolytes in animal models. The evidence also was observed in scientific reviews and literature that discuss the traditional applications of the Lespedeza plant genus for conditions associated with acute or disruptive episodes of water retention. The data show patterns related to this supportive action, often referenced in the context of the plant’s use to address edema.

Understanding the Evidence Gaps and Uncertainties

A primary research gap is the absence of published, product-specific, randomized controlled trials (RCTs) conducted in human patients. This means the evidence is limited in its ability to confirm clinical symptomatic effects. The current evidence mainly represents pre-clinical (animal) studies, which can only offer supportive context. Long-term effects are not fully established because follow-up durations were limited, and certainty remains low regarding the comprehensive clinical profile and outcomes of this medicine.

Common questions about Леспефлан (FAQ)

Q: Does Леспефлан only treat symptoms, or does it address the cause?

A: Леспефлан is officially categorized as a hypoazotemic agent. This function is centered on supporting the excretory system by facilitating the renal elimination of nitrogenous waste products like urea and creatinine, which are metabolites. This function is achieved by facilitating the renal elimination of nitrogenous waste products, which helps reduce their circulating concentration.

Q: What are the general expectations for the overall treatment outcome with Леспефлан?

A: Official research has primarily focused on pre-clinical studies, describing the extract's effect on biomarkers like urea and creatinine in animal models. The available evidence is limited by the absence of published, product-specific, randomized controlled trials conducted in human patients. This structure limits the ability to define clinical symptomatic effects or general expectations for patient outcomes based on available trials.

Q: Is it necessary to complete the full course of Леспефлан, even if symptoms improve quickly?

A: The regulatory protocol mandates a defined treatment course, typically between three and four weeks in duration. This structure outlines the prescribed cycle of use, which includes a mandatory break period of two to three weeks before any subsequent course. Always follow the guidelines defined in the regulatory information.

Q: Are there any specific side effects that are considered very common with Леспефлан?

A: The official regulatory documents state the medicine is associated with the possibility of allergic reactions. Hyponatremia (abnormally low sodium levels) is also reported in rare cases. However, the official product information does not provide a comprehensive classification of adverse reactions by standard frequency categories like 'very common' or 'common.'

Q: Can Леспефлан affect sleep patterns according to regulatory information?

A: The regulatory safety notes warn that the medicine may cause a decrease in the speed of psychomotor reactions, which affects activities requiring high concentration. While this is noted, the official labeling does not explicitly mention effects on sleep patterns or insomnia.

Q: Are there any specific foods or drinks that should be avoided when using Леспефлан?

A: The official regulatory information for this product is characterized by the lack of explicit warnings across all standardized interaction categories. This means the government-approved documentation does not contain formal statements restricting specific foods or drinks.

Q: Are there certain substances that are known to reduce the effectiveness of Леспефлан?

A: The official regulatory profile for this medicine does not contain formal statements regarding contraindicated combinations or required dose-timing separations. This structure reflects that specific, restrictive warnings regarding substances that reduce effectiveness have not been mandated by regulatory authorities.

Q: Is it true that Леспефлан should not be combined with other herbal supplements?

A: According to the official regulatory profile, there is a lack of explicit warnings regarding interactions across all standardized categories. This means the government-approved documentation does not contain formal statements advising against combining Леспефлан with other supplements or herbal medicinal products.

Q: What does the term 'contraindication' mean in the context of Леспефлан?

A: A contraindication establishes the populations and pre-existing conditions where the product must not be used. For Леспефлан, this includes certain physiological states and conditions, such as pregnancy and liver diseases, which define the product's regulatory safety boundaries.

Q: Is Леспефлан considered appropriate for long-term or maintenance use, based on available research?

A: The regulatory administration protocol defines a standard treatment course of three to four weeks, with a potential extension up to six weeks based on professional guidance. While use for several weeks is allowed, the available research evidence has limited follow-up durations, and long-term effects beyond the typical treatment course are not fully established.

Q: Does traveling with Леспефлан require any special storage considerations?

A: The product must be stored at a controlled room temperature, generally not exceeding 25 C, in a dry place, and protected from light. The product must be stored under these specific environmental conditions, whether at home or during travel.

How to Store and Dispose of Леспефлан?

Леспефлан (Lespeflan) must be stored under specific environmental conditions to maintain its quality and stability, as defined by regulatory documents.

Official Storage Conditions

The product must be stored at a controlled room temperature, generally not exceeding 25 C, with some labels specifying a range of 15 C to 25 C. The medicine requires protection from environmental factors and must be kept in a dry place and protected from light.

Stability and Safety

The overall shelf life typically ranges from two to four years when stored correctly. It is mandatory not to use the product after the expiration date. Crucially, the medicine must be stored out of the reach of children.

Disposal

Official regulatory labeling does not provide explicit, detailed instructions for the disposal of unused or expired product. Discarding must be performed in accordance with local pharmaceutical waste regulations.